Balyasny Asset Management
MRNA icon

Balyasny Asset Management’s Moderna MRNA Stock Holding History

Balyasny Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.52M Buy
107,418
+102,227
+1,969% +$5.29M 0.01% 1195
2026
Q1 		$264K Sell
5,191
-8,599
-62% -$401K ﹤0.01% 2611
2025
Q4 		$407K Sell
13,790
-613,695
-98% -$16.7M ﹤0.01% 2611
2025
Q3 		$16.2M Buy
+627,485
New +$17.5M 0.02% 809
2024
Q4 		– Sell
-13,574
Closed -$649K – 3077
2024
Q3 		$907K Sell
13,574
-26,802
-66% -$2.46M ﹤0.01% 2012
2024
Q2 		$4.79M Buy
40,376
+30,076
+292% +$3.81M 0.01% 1190
2024
Q1 		$1.1M Buy
+10,300
New +$1.04M ﹤0.01% 1744
2023
Q4 		– Sell
-700,341
Closed -$72.3M – 2747
2023
Q3 		$72.3M Buy
700,341
+386,625
+123% +$43.1M 0.15% 179
2023
Q2 		$38.1M Buy
313,716
+308,504
+5,919% +$41.2M 0.08% 322
2023
Q1 		$800K Sell
5,212
-149,900
-97% -$24.7M ﹤0.01% 1816
2022
Q4 		$27.9M Buy
+155,112
New +$25.4M 0.08% 346
2022
Q3 		– Sell
-37,377
Closed -$5.67M – 3115
2022
Q2 		$5.34M Buy
+37,377
New +$5.34M 0.02% 902
2022
Q1 		– Sell
-66,529
Closed -$11.2M – 2702
2021
Q4 		$16.9M Buy
+66,529
New +$19.5M 0.06% 479
2020
Q3 		– Sell
-481,631
Closed -$30.9M – 1479
2020
Q2 		$30.9M Buy
+481,631
New +$26.4M 0.27% 90
2019
Q4 		– Sell
-11,557
Closed -$184K – 1364
2019
Q3 		$184K Sell
11,557
-37,420
-76% -$553K ﹤0.01% 1083
2019
Q2 		$717K Buy
+48,977
New +$1.05M ﹤0.01% 1154

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Balyasny Asset Management's MRNA Position: Q2 2026 in Review

Balyasny Asset Management increased its Moderna (MRNA) stake by 1,969% in Q2 2026, buying an estimated $5.29M and bringing the position to 107,418 shares worth $7.52M. The position accounts for 0.01% of the portfolio, ranked #1195.

Balyasny Asset Management first reported a position in MRNA in Q2 2019 and has held it in 16 quarters since. The position peaked at $72.3M in Q3 2023. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Balyasny Asset Management held 107,418 shares of Moderna worth $7.52M as of Q2 2026.
  • Balyasny Asset Management bought 102,227 Moderna shares in Q2 2026, an estimated $5.29M.
  • Moderna made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1195 holding.
  • Balyasny Asset Management first reported a position in Moderna in Q2 2019 and has held it in 16 quarters since.
  • Balyasny Asset Management's Moderna position peaked at $72.3M in Q3 2023.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.